Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Happy Thursday. Today, we report on expectations President Trump will unveil more pricing deals with pharma, see new FDA labeling that could affect Pfizer in court, and more.
The need-to-know this morning
- Takeda said its oral drug zasocitinib induced “clear or almost clear skin” in more than half of patients with moderate to severe plaque psoriasis. Approximately 30% of patients achieved “completely clear skin.” The drug achieved all the efficacy goals of two randomized, controlled Phase 3 clinical trials. Takeda intends to submit zasocitinib for FDA approval in 2026.
Lilly’s pill helped as a maintenance therapy
Eli Lilly announced this morning that its investigational obesity pill largely helped patients maintain their weight loss after they switched from injectable treatments Wegovy and Zepbound, results that could widen the appeal for the pill.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply